MedTrace Logo

Tolerability of SLIT With LAIS® 2-Tree Allergoid Tablets

NCT02553590 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2015-11-11

No results posted yet for this study

Summary

To expand knowledge on the application and tolerability of immunotherapy with LAIS® 2-tree allergoid tablets as well as knowledge on the alleviation of symptoms during sublingual therapy in special consideration of the chosen titration schedule in everyday practice.

Conditions

  • Allergic Rhinitis

Sponsors & Collaborators

  • University Hospital of Cologne

    lead OTHER

Principal Investigators

  • Ralph Mösges, Professor · University Hospital of Cologne

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02553590 on ClinicalTrials.gov